TITLE

ACTIONS OF IRBESARTAN ON ATPASE ACTIVITY AND ANGIOTENSIN II IN BLOOD VESSELS FROM RENAL HYPERTENSIVE RATS

PUB. DATE
October 2010
SOURCE
Heart;Oct2010 Supplement, pA106
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
An abstract of the article "Actions of Irbesartan of ATPase Activity and Angiotensin II in Blood Vessels From Renal Hypertensive Rats" by Qian-Hui Shang and colleagues is presented.
ACCESSION #
66245734

 

Related Articles

  • Pleiotropic effects of angiotensin II blockers in hemodialysis patients: myth or reality? Zoccali, Carmine; Mallamaci, Francesca // Kidney International;Sep2014, Vol. 86 Issue 3, p469 

    Mechanistic studies suggest that angiotensin II receptor blockers (ARBs) may have pleiotropic effects on the cardiovascular system in hemodialysis patients. A new randomized trial by Peters et al. failed to show a benefit of irbesartan on biomarkers of arterial stiffness, left ventricular mass,...

  • Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria. Andersen, Sten; Mischak, Harald; Zürbig, Petra; Parving, Hans-Henrik; Rossing, Peter // BMC Nephrology;2010, Vol. 11, p29 

    Background: Previously the angiotensin II receptor blocker Irbesartan has been demonstrated to reduce the risk for progression from microalbuminuria to macroalbuminuria in type 2 diabetic patients. The purpose of this study was to evaluate the effect of treatment with Irbesartan in type 2...

  • Mechanisms involved in renal hypertension. Bianchl, G.; Fox, U.; Pagetti, D.; Caravaggi, A. M.; Bafr, P. G.; Baldoli, E. // Kidney International Supplement;Sep1975, Issue 5, p165 

    Examines the role of the kidney in the pathogenesis of essential hypertension. Association of hypertension with renal disease; Variation of the importance of sodium retention and renin secretion according to the type of renal lesion; Measurement of the changes of plasma angiotensin II...

  • NICE-Combi Study: Effect of Nifedipine in Combination with an Angiotensin II Receptor Blocker on BP Control and Renal Protection. Hasebe, Naoyuki // Drugs;2006 Special Issue I1, Vol. 66, p16 

    Combination of antihypertensive drugs which have different mechanisms of action need to be considered to achieve the goal of therapy recommended in guidelines for the treatment of hypertension. However, there are few data on the most suitable combinations for antihypertensive therapy. The...

  • Microalbuminuria y factores de riesgo cardiovascular asociados en pacientes con hipertensi�n arterial sist�mica. Suban�lisis del estudio I-Search. Lomel�, Catalina; Rosas-Peralta, Mart�n; Lorenzo, Antonio; Saucedo, N�stor // Archivos de Cardiolog�a de M�xico;abr-jun2012, Vol. 82 Issue 2, p93 

    Objectives: To establish the prevalence of microalbuminuria in a group of patients with systemic arterial hypertension (SAH) to analyze the association between this parameter and cardiovascular risk factors as well as with SAH treatment. Methods: This is a sub-analysis of 564 patients of Mexico,...

  • Formulation and evaluation of irbesartan fast dissolving tablets. Ramu, Anne; Vidyadhara, Suyadevara; Devanna, Nayakanti; Thirumala Naidu, Uttlapalli; Lakshmi Kalyani, Pavuluri // Asian Journal of Pharmaceutics (Medknow Publications & Media Pvt;Apr-Jun2013, Vol. 7 Issue 2, p61 

    Solid dispersions of irbesartan with poly ethylene glycol (PEG-6000) were prepared and further compressed as tablets by using superdisintegrants such as croscarmellose sodium, crospovidone, sodium starch glycolate (SSG). The solid dispersions of irbesartan with PEG-6000 at different ratios were...

  • DEVELOPMENT AND VALIDATION OF A STABILITY-INDICATING RP-HPLC METHOD FOR ASSAY OF IRBESARTAN IN PURE AND PHARMACEUTICAL DOSAGE FORM. Kumar, Praveen M.; Sreeramulu, J. // International Journal of Pharmaceutical Sciences Review & Resear;Jan/Feb2011, Vol. 6 Issue 1, p94 

    A novel stability-indicating gradient reverse phase-high performance liquid chromatographic (RP-HPLC) method was developed for the determination of Irbesartan in pure and pharmaceutical dosage form was developed and validated. The chromatographic conditions comprised of a reversed-phase C18...

  • Bioequivalence study of 300 mg irbesartan film-coated tablets preparations in healthy Thai volunteers. Puranajoti, Porranee; Werarak, Peerawong; Intawong, Burapat; Hongrapipat, Jarunee; Talubsri, Rungrudee; Sangsuriyawong, Soravee; Kuamsuk, Temsiri // Thai Journal of Pharmaceutical Sciences;2013, Vol. 37 Issue 4, p186 

    Irbesartan, an angiotensin II receptor antagonist, is indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents. The purpose of this study was to compare the bioavailability of two formulations of irbesartan 300 mg film-coated tablets...

  • New UPLC-MS/MS method for simultaneous determination of irbesartan and hydrochlorthiazide in human plasma. Zargar, Seema; Wani, Tanveer // Journal of the Iranian Chemical Society;Dec2014, Vol. 11 Issue 6, p1579 

    Ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) is a preeminent analytical tool for rapid biomedical analysis with the objective of reducing analysis time and maintaining good efficiency. In this study a simple, rapid, sensitive and specific ultra-performance liquid...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics